Skip to main content
Clinical Trials/NCT04537455
NCT04537455
Completed
Not Applicable

Non-invasive Mapping Using Ultra-high Frequency Electrocardiography

Imperial College London1 site in 1 country30 target enrollmentOctober 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Left Bundle-Branch Block
Sponsor
Imperial College London
Enrollment
30
Locations
1
Primary Endpoint
Number of patients with block in the proximal conduction system
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Cardiac electrical mapping is an important tool that allows doctors to study the electrical activity of the heart in detail. Electrical mapping systems used in clinical practice are time consuming, invasive and very costly. Ultra-high frequency electrocardiography is a novel non-invasive cardiac mapping system. Ultra-high frequency electrocardiography (UHF-ECG) can be performed in 10-15 minutes without any risk or discomfort to patients.

The aim of this study is to refine this mapping system, verify it against invasive mapping and develop software to bring this novel system into routine clinical use including predicting which patients will respond to cardiac resynchronisation therapy.

Detailed Description

This is a single centre laboratory study aiming to utilise ultra-high frequency electrocardiography to construct cardiac electrical activation maps. All participants will attend for an UHF-ECG. This involves placing standard electrocardiography electrodes (up to 48) followed by electrocardiography recording using the UHF-ECG machine for 10-15 minutes. Participants undergoing a clinically indicated VT ablation procedure will their UHF-ECG done before the procedure at a separate time. The ablation procedure itself will proceed as standard with no alternation whatsoever in study participants and no invasive measurements will be undertaken during the procedure. After the procedure is complete the 3D electrical maps collected to guide VT ablation will be analyzed and used for the study. The invasive maps will be compared with the non-invasive maps obtained using UHF-EGC.

Registry
clinicaltrials.gov
Start Date
October 1, 2019
End Date
March 10, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults (age \> 18 years)
  • Able to give consent
  • Some patients will be recruited from those listed for a clinically indicated VT ablation
  • Patient subgroups as follows; 60 participants with LBBB undergoing a clinically indicated VT ablation , 20 participants with normal 12 lead ECG and normal left ventricular function assessed using standard echocardiography, 20 participants with right bundle branch block morphology on 12 lead ECG, 40 participants with non-specific conduction delay on 12 lead ECG, 60 participants with left bundle branch block morphology on 12 lead ECG and 20 participants who developed left bundle branch block morphology on 12 lead ECG after undergoing aortic valve replacement

Exclusion Criteria

  • Unable to give consent
  • Children (age \< 18 years)

Outcomes

Primary Outcomes

Number of patients with block in the proximal conduction system

Time Frame: 3 years

number of participant with an electrical activation map where the pattern indicates proximal conduction disease.

Study Sites (1)

Loading locations...

Similar Trials